These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1033 related articles for article (PubMed ID: 33137809)

  • 41. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Bahar B; Jacquot C; Mo YD; DeBiasi RL; Campos J; Delaney M
    J Pediatr; 2020 Dec; 227():31-37.e1. PubMed ID: 32891640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Sex/gender differences in COVID-19 lethality: what the data say, and do not say].
    Mangia C; Russo A; Civitelli S; Gianicolo EAL
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):400-406. PubMed ID: 33412835
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics in Pediatric Patients with Coronavirus Disease 2019 in Korea.
    Seon JY; Jeon WH; Bae SC; Eun BL; Choung JT; Oh IH
    J Korean Med Sci; 2021 May; 36(20):e148. PubMed ID: 34032033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. One hundred thirty-three observed COVID-19 deaths in 10 months: unpacking lower than predicted mortality in Rwanda.
    Musanabaganwa C; Cubaka V; Mpabuka E; Semakula M; Nahayo E; Hedt-Gauthier BL; Ng KCS; Murray MB; Kateera F; Mutesa L; Nsanzimana S
    BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33627363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada.
    Hoffmann C; Wolf E
    Infection; 2021 Feb; 49(1):111-116. PubMed ID: 33098532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population Immunity Against COVID-19 in the United States.
    Moghadas SM; Sah P; Shoukat A; Meyers LA; Galvani AP
    Ann Intern Med; 2021 Nov; 174(11):1586-1591. PubMed ID: 34516275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands.
    McDonald SA; Miura F; Vos ERA; van Boven M; de Melker HE; van der Klis FRM; van Binnendijk RS; den Hartog G; Wallinga J
    Eur J Epidemiol; 2021 Jul; 36(7):735-739. PubMed ID: 34114187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure.
    Demonbreun AR; McDade TW; Pesce L; Vaught LA; Reiser NL; Bogdanovic E; Velez MP; Hsieh RR; Simons LM; Saber R; Ryan DT; Ison MG; Hultquist JF; Wilkins JT; D'Aquila RT; Mustanski B; McNally EM
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33755598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar.
    Seedat S; Chemaitelly H; Ayoub HH; Makhoul M; Mumtaz GR; Al Kanaani Z; Al Khal A; Al Kuwari E; Butt AA; Coyle P; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Yassine HM; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Bertollini R; Abu-Raddad LJ
    Sci Rep; 2021 Sep; 11(1):18182. PubMed ID: 34521903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cross-reactive antibody immunity against SARS-CoV-2 in children and adults.
    Fraley E; LeMaster C; Banerjee D; Khanal S; Selvarangan R; Bradley T
    Cell Mol Immunol; 2021 Jul; 18(7):1826-1828. PubMed ID: 34059791
    [No Abstract]   [Full Text] [Related]  

  • 53. Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic, March to December 2020.
    Shiels MS; Haque AT; Haozous EA; Albert PS; Almeida JS; García-Closas M; Nápoles AM; Pérez-Stable EJ; Freedman ND; Berrington de González A
    Ann Intern Med; 2021 Dec; 174(12):1693-1699. PubMed ID: 34606321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India.
    Selvaraju S; Kumar MS; Thangaraj JWV; Bhatnagar T; Saravanakumar V; Kumar CPG; Sekar K; Ilayaperumal E; Sabarinathan R; Jagadeesan M; Hemalatha MS; Murhekar MV;
    Emerg Infect Dis; 2021 Feb; 27(2):586-589. PubMed ID: 33496222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
    COVID-19 National Preparedness Collaborators
    Lancet; 2022 Apr; 399(10334):1489-1512. PubMed ID: 35120592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Age-stratified infection fatality rate of COVID-19 in the non-elderly population.
    Pezzullo AM; Axfors C; Contopoulos-Ioannidis DG; Apostolatos A; Ioannidis JPA
    Environ Res; 2023 Jan; 216(Pt 3):114655. PubMed ID: 36341800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Children aged 0-14 years had a far lower mortality risk during the entire COVID-19 pandemic in four major industrial countries: an observational study.
    Yuan L; Sun C; Zeng Z; Wang H
    Eur J Pediatr; 2024 Jun; 183(6):2645-2653. PubMed ID: 38502322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China.
    Porcheddu R; Serra C; Kelvin D; Kelvin N; Rubino S
    J Infect Dev Ctries; 2020 Feb; 14(2):125-128. PubMed ID: 32146445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Excess Mortality Associated With COVID-19 by Demographic Group: Evidence From Florida and Ohio.
    Quast T; Andel R
    Public Health Rep; 2021; 136(6):782-790. PubMed ID: 34436948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.